Mineralys Therapeutics, Inc. (MLYS)
(Delayed Data from NSDQ)
$13.46 USD
+0.05 (0.37%)
Updated Aug 6, 2025 04:00 PM ET
After-Market: $13.45 -0.01 (-0.07%) 7:58 PM ET
2-Buy of 5 2
D Value F Growth B Momentum F VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
MLYS 13.46 +0.05(0.37%)
Will MLYS be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for MLYS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for MLYS
Mineralys Therapeutics, Inc. (MLYS) Upgraded to Buy: Here's Why
Does Mineralys Therapeutics, Inc. (MLYS) Have the Potential to Rally 154.21% as Wall Street Analysts Expect?
MLYS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Here's Why Momentum in Mineralys Therapeutics, Inc. (MLYS) Should Keep going
Here's Why Mineralys Therapeutics, Inc. (MLYS) is a Great Momentum Stock to Buy
Other News for MLYS
MLYS Crosses Below Key Moving Average Level
Mineralys Therapeutics to Announce Second Quarter 2025 Financial Results and Host Conference ...
Franklin Biotechnology Discovery Fund Q2 2025 Commentary
Insider Sell: Adam Levy Sells 73,678 Shares of Mineralys Therapeutics Inc (MLYS)
Insider Sell: CEO Jon Congleton Sells Shares of Mineralys Therapeutics Inc (MLYS)